結果 : checkmate 227 study design
44:56

Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic Landscape

HMP Education
3,984 回視聴 - 3 年前
6:13

CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLC

OncLive
413 回視聴 - 6 年前
11:59

Solange Peters, Switzerland: CheckMate 227 Part 1 final analysis

Oncoletter
537 回視聴 - 5 年前
5:31

CheckMate-227: Nivolumab + Ipilimumab in mNSCLC

OncLive
239 回視聴 - 6 年前
17:08

Three-Year Update From the CheckMate 227 Clinical Trial for Advanced NSCLC

OncLive
838 回視聴 - 4 年前
10:12

Nivolumab + Ipilimumab + 2 Cycles of Platinum-doublet Chemo vs 4 Cycles Chemo for Stage IV NSCLC

MedEdOTG
80 回視聴 - 4 年前
5:25

Dual Checkpoint Inhibition in NSCLC: CheckMate-227

Targeted Oncology
63 回視聴 - 6 年前
3:45

Researcher comment: Take-home messages from the CheckMate 227 trial | Solange Peters

Medicine Matters oncology
218 回視聴 - 4 年前
9:14

Results from CheckMate-227 : Immune combination reaches PFS endpoint

ecancer
209 回視聴 - 6 年前
2:19

David Spigel, MD, tells us about the results of CheckMate-227 presented at ESMO 2019

OBRoncology
96 回視聴 - 4 年前
32:12

Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): Front Line Therapy

HMP Education
13,592 回視聴 - 3 年前
11:44

CheckMate 227 dual IO therapy: nivo plus ipilimumab upfront for NSCLC

VJOncology
1,440 回視聴 - 5 年前
0:52

Dr. Hellmann on the Design of the CheckMate-032 Study for Lung Cancer

OncLive
338 回視聴 - 7 年前
9:40

Are TMB and Nivolumab/Ipilimumab Ready for Clinical Use? Insights from CheckMate 227 (BMIC-035)

BeaconMedIC
601 回視聴 - 6 年前
8:57

Nivo/Ipi Rx of Choice for Adv. NSCLC, PD-L1 Under 1%, High TMB? New CheckMate 227 Data (BMIC-040)

BeaconMedIC
152 回視聴 - 6 年前
7:58

Long-Term Survival with Nivolumab + Ipilimumab in Advanced NSCLC | Dr. Sandeep Ishi | CRSF 2023

CRSF - Cancer Research and Statistic Foundation
15 回視聴 - 3 か月前
1:16:00

Case by Case: Optimizing Dual Immune Checkpoint Inhibitor Combination Therapies in Advanced Drive...

ReachMD
36 回視聴 - 2 か月前
25:26

Locally advanced NSCLC: Combination therapy with targeted and immunotherapy agents

HMP Education
1,258 回視聴 - 6 年前
21:39

The role of Immunotherapy in stage IV NSCLC (PDL1 high/low)Dr. Julian Molina Day 2

Oncology Events
192 回視聴 - 3 年前
1:03:39

Deep Insight Into Immuno-Oncology: Immunotherapy Pathways, Targets, and Biomarkers

PeerView Oncology
78,055 回視聴 - 4 年前